By silencing the receptor tyrosine kinases expressed on fibroblast cells such as FAK and VEGFR, PF562271 [43] and regorafenib treatment [44] reduced populations of fibroblast and interrupting the interaction of tumour cells with stromal cells, resulted in cancer regression. This evidence concerns the gene PTK2 and neoplasm.